Trialbee, a company offering an array of patient enrollment and matching technologies, has announced it will offer the patient recruitment platform for Ergomed’s new Rare Disease Innovation Center. The partnership will combine Trialbee’s real-world data (RWD) and technology with Ergomed’s Site Advantage in an effort to make recruitment more efficient, increase patient centricity, and bring new rare disease treatments to market more rapidly.
The news of the partnership (and of the center's opening) was announced to coincide with Rare Disease Day, an occasion designed to increase awareness of the uncommon conditions that approximately 400m people around the globe have been diagnosed with. According to statistics, 95% of rare diseases have no therapy approved by the US Food and Drug Administration (FDA).
“This partnership is about impacting global rare disease research in a meaningful way for our industry,” said Matt Walz, CEO of Trialbee. “By providing a global patient referral ecosystem with Trialbee Hive, triaged through a single onboarding platform with Trialbee Honey, and fully enabled by Ergomed Site Advantage, we provide patients a frictionless journey into clinical research for rare disease, while reducing the enrollment on sites.”
Currently, approximately 30% of all investigational products globally are intended for rare diseases. Ergomed’s Site Advantage operating model is engineered to provide sites and patient participants involved in rare disease studies with specialized support. Trialbee’s RWD-powered recruitment engine and software-as-a-service (SaaS) based enrollment platform will be used to identify, recruit and enroll participants for the Rare Disease Innovation Center.
“Rare disease drug development is one of the fastest-growing areas in drug development with a 12-14% annual growth rate, accounting for about one-third of the drugs in development,” said Zizi Uzezi Imatorbhebhe, senior vice president of global strategy and development and head for Ergomed’s Rare Disease Innovation Center. “We are thrilled to partner with Trialbee as we launch our Rare Disease Innovation Center; this will leverage Ergomed’s experience in doing hundreds of rare disease studies in conjunction with innovative approaches from Trialbee to help rare disease sponsors and sites address challenges in rare disease patient recruitment.”
Additionally, Trialbee will serve as the patient identification partner for the center, which offers trial management services for pharmaceutical companies around the world. Ergomed reportedly will use Trialbee Hive to augment referrals and find patients. Trialbee Honey will be used to help increase transparency and inclusivity, and accelerate recruitment, by tracking referrals at sites.
Rare and genetic diseases took center stage at Outsourcing-Pharma’s recent Rare and Orphan Diseases webinar. To hear from the three industry expert presenters, register to view the webinar on-demand here.
